SCHEMBL1743033

SCHEMBL1743033

O=C(Nc1ccc(-c2ccc(N3CCN(C4CC4)CC3)nn2)cc1)C1CCCCC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.55
PTPN2 P17706 1/20 0.55
NPC1 O15118 9/20 0.54
RAB9A P51151 8/20 0.54
KDM4E B2RXH2 2/20 0.52
ALDH1A1 P00352 2/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
PPARG P37231 1/20 0.49
NR2E3 Q9Y5X4 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
TP53 P04637 3/20 0.45
HPGD P15428 2/20 0.45
PKM P14618 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
MAPT P10636 2/20 0.44
POLB P06746 1/20 0.44
MDM2 Q00987 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1743048 0.95 NPC1 (0.57) PTPN1PTPN2NPC1RAB9AKDM4E
SCHEMBL1744595 0.93 NPC1 (0.56) PTPN1PTPN2NPC1RAB9AKDM4E
SCHEMBL1743158 0.84 NPC1 (0.58) NPC1RAB9AKDM4EMEN1KMT2A
SCHEMBL1742397 0.83 NPC1 (0.57) NPC1RAB9AMEN1KMT2APPARG
SCHEMBL1742303 0.82 NPC1 (0.60) NPC1RAB9AMEN1KMT2A
SCHEMBL1744217 0.78 SCD (0.54) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL3043622 0.76 HRH3 (0.48) NPC1RAB9AMEN1KMT2ATP53
SCHEMBL1744201 0.76 HRH3 (0.56) KDM4EALDH1A1MEN1KMT2APOLB
SCHEMBL4496153 0.75 HRH3 (0.45) NPC1RAB9AMEN1KMT2APPARG
SCHEMBL3967998 0.74 MAPT (0.51) ALDH1A1MAPK1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP claimed
US-8846677-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2014-09-30 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-8501739-B2 Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2013-08-06 US disclosed
US-20120232078-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2012-09-13 US disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
EP-2386554-A1 Compounds active at the histamine H3 receptor High Point Pharmaceuticals, LLC (US) 2011-11-16 EP disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed
US-20090312309-A1 Novel Medicaments HIGH POINT PHARMACEUTICALS, LLC (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232078-A1 Novel Medicaments HRH3, HRH4, HRH1 PTPN1 3314/4885PTPN2 3019/4885NPC1 2646/4885
US-20090312309-A1 Novel Medicaments HRH3, HRH4, HRH1 PTPN1 3314/4885PTPN2 3019/4885NPC1 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.